Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

OTCQB:BIXT - Post by User

Bioxytran Inc

<< Previous

Bullboard Posts

Next >>

Post by amritadaniqueon Oct 26, 2023 8:58am

86 Views

Post# 35701755

"$BIXT Valuation Highlights Promising Biotech Potential"

The present market capitalization of Bioxytran, Inc. ($BIXT) stands at $23.09 million, reflecting its promising potential in the biotech industry. This valuation underscores the company's commitment to advancing healthcare and addressing critical medical challenges, particularly in the fields of glycovirology, hypoxia, and degenerative diseases. With innovative solutions in the pipeline, Bioxytran is on a path to positively impact patient well-being and medical science.

<< Previous

Bullboard Posts

Next >>

Here are three global stocks you should watch